Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2578763 | Thérapie | 2015 | 8 Pages |
Abstract
In May 2014, the European Union Parliament and Council published a new regulation on clinical trials on medicinal products for human use, which is designed to replace Directive 2001/20/EC. It will not come into effect until 2016. Nevertheless, it is essential to examine its relationship with national legislation, i.e. the Jardé Act, whose implementation has been delayed pending publication of the European regulation. The Giens workshop identified and examined the various issues that this relationship is bound to raise. In particular, it looked at trial methodology assessment procedures, the working relationship between the French National Agency of Drug Safety and Health Products (Agence Nationale de Sécurité du Médicament et des Produits de Santé, ANSM) and ethics committees during the authorization application evaluation phase, review of post-authorization/registration studies on medicinal products and medical devices, and data transparency.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology, Toxicology and Pharmaceutics (General)
Authors
François Lemaire, Brigitte Marchenay, Olivier Chassany, Laetitia Gambotti, the participants of round table N°2 of Giens XXX: the participants of round table N°2 of Giens XXX:, Philippe Barthélémy, Mohamed Bouzzagou, Denis Comet, Cécile Delval,